TY  - JOUR
AU  - Borghaei, Hossein
AU  - Gettinger, Scott
AU  - Vokes, Everett E
AU  - Chow, Laura Q M
AU  - Burgio, Marco Angelo
AU  - de Castro Carpeno, Javier
AU  - Pluzanski, Adam
AU  - Arrieta, Oscar
AU  - Frontera, Osvaldo Arén
AU  - Chiari, Rita
AU  - Butts, Charles
AU  - Wójcik-Tomaszewska, Joanna
AU  - Coudert, Bruno
AU  - Garassino, Marina Chiara
AU  - Ready, Neal
AU  - Felip, Enriqueta
AU  - García, Miriam Alonso
AU  - Waterhouse, David
AU  - Domine, Manuel
AU  - Barlesi, Fabrice
AU  - Antonia, Scott
AU  - Wohlleber, Markus
AU  - Gerber, David E
AU  - Czyzewicz, Grzegorz
AU  - Spigel, David R
AU  - Crino, Lucio
AU  - Eberhardt, Wilfried Enst Erich
AU  - Li, Ang
AU  - Marimuthu, Sathiya
AU  - Brahmer, Julie
PY  - 2021
DO  - 10.1200/JCO.20.01605
UR  - http://hdl.handle.net/10668/16983
T2  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
AB  - Immunotherapy has revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab showed an improvement in overall survival (OS) and favorable safety versus docetaxel in...
LA  - en
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Clinical Trials, Phase III as Topic
KW  - Disease Progression
KW  - Docetaxel
KW  - Female
KW  - Humans
KW  - Immune Checkpoint Inhibitors
KW  - Immunotherapy
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Nivolumab
KW  - Progression-Free Survival
KW  - Randomized Controlled Trials as Topic
KW  - Time Factors
KW  - Tubulin Modulators
KW  - Young Adult
TI  - Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
TY  - research article
VL  - 39
ER  -